ALBUQUERQUE, N.M. (KRQE) – The Lovelace Heart Hospital is celebrating the new addition of their 1,000th heart device. Called ...

Boston Scientific announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX device.

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global ...

Boston Scientific Corp. (BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the ...

Baystate Medical Center now offers this minimally invasive surgery where a left atrial appendage closure device is implanted into your heart. The WATCHMAN device closes off your LAA to keep blood ...

The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent ...

The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.

The Cottage Heart & Vascular Center’s structural heart team at Santa Barbara Cottage Hospital (SBCH) recently performed their ...

Abbott (NYSE:ABT) announced new data supporting its Amplatzer Amulet left atrial appendage (LAA) occluder system.

(BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrirl Appendage Closure (LAAC) Device. The device demonstrated superior ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

The WATCHMAN FLX device showed superior safety with 8.5% major bleeding at 36 months, compared to 18.1% with oral ...